AIFM2 and lung carcinoma: The pharmacologic inhibition of FSP1, which generates the radical-trapping antioxidant ubiquinol independently of GSH, has shown preclinical promise, particularly in lung cancer models where FSP1 appears crucial for in vivo tumor survival [165,166].